Dingke

Quick links to important sections

Dingke

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dingke

Quick Facts

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Oral Tablets, Cream, Gel, or Spray
Pharmacological Class Allylamine Antifungal Medication
General Purpose To kill fungal cells (Fungicidal agent)
Origin Synthetic Compound

What Type of Medicine is Dingke and What is its Core Purpose?

Dingke is a specific pharmaceutical preparation containing the active component Terbinafine Hydrochloride, a synthetic, small-molecule agent classified within the allylamine antifungal pharmacological class. This compound is recognized as a potent substance specifically developed to fight infections caused by dermatophytes and other susceptible fungi. The core purpose of the drug is its ability to achieve a robust fungicidal effect against the targeted pathogens.

Terbinafine is a single-ingredient product, and its classification as an allylamine highlights a key differentiating feature: the drug is clinically recognized for its high selectivity, preferentially targeting fungal cellular processes.

Composition, Origin, and Available Forms

The foundational substance of the medicine is Terbinafine Hydrochloride, confirming its synthetic origin. This active ingredient is prepared to facilitate various routes of administration, distinguishing it from many antifungals available only in one form. For comprehensive treatment, it is formulated as the oral tablet for systemic delivery. Conversely, for localized skin issues, the medicine is available in topical dosage forms such as a cream, gel, or spray, where Terbinafine Hydrochloride is dispersed in an appropriate base/vehicle for direct surface application.

High-Level Action Against Fungi

The potent action of Terbinafine is based on its ability to interfere with the fungal cell's structural integrity. The drug achieves this by selectively inhibiting the enzyme squalene epoxidase, a critical enzyme necessary for the fungal cell's production of ergosterol. This unique inhibition leads to the toxic accumulation of a precursor substance called squalene within the fungal cell, which causes significant cell damage. This distinct mechanism ultimately results in the destruction of the fungal pathogen.

Regulatory References

  1. NIH StatPearls: Terbinafine

What side effects are possible with Dingke?

Possible Side Effects and Safety Information

Dingke (Terbinafine Hydrochloride) has a formally documented safety profile in regulatory sources that classifies possible effects by frequency and system involvement. Very Common or Common adverse reactions typically affect the Gastrointestinal Disorders system and include diarrhea, dyspepsia, abdominal pain, nausea, and headache. Taste disturbance (dysgeusia), liver enzyme abnormalities, rash, and pruritus are also commonly reported.

Serious Adverse Reactions and Restrictions

Official labeling documents the potential for rare but serious adverse reactions, particularly involving the Hepatobiliary Disorders system. Rare cases of liver failure, sometimes resulting in death or transplant, have been reported, necessitating pretreatment liver function tests. These serious hepatic events have been observed to usually occur within two months of treatment initiation. Other very rare but clinically important reactions include severe skin reactions (e.g., Stevens-Johnson Syndrome, DRESS syndrome), severe blood dyscrasias (neutropenia, pancytopenia), and thrombotic microangiopathy.

Population and Time-Related Safety Notes

Dingke is formally contraindicated in individuals with pre-existing active or chronic liver disease. Use is generally not recommended in patients with renal impairment. Taste and smell disturbances are recognized as potential adverse effects that may be prolonged, lasting over one year, or may become permanent. The medicine is classified as a potent inhibitor of the CYP2D6 isoenzyme, a key safety consideration when co-administered with other medicines metabolized by this enzyme.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the clinical presentation and required emergency response actions in the event of an overdose.

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Symptoms reported in documented cases include nausea, vomiting, abdominal pain, headache, dizziness, rash, and frequent urination
Physiological systems affected Primarily the Gastrointestinal and Central Nervous Systems
Dose-related or exposure-related factors Documented oral overdose cases up to five grams have been reported without inducing serious adverse reactions
Population-specific overdose notes The severity of systemic events may be worse in patients with active or chronic liver disease
Emergency-response statements Treatment consists of symptomatic and supportive therapy; no specific antidote is known
When immediate medical help is required Contact a poison control center or emergency room at once if an overdose is suspected. Seek emergency services immediately if the person collapses, has a seizure, or has difficulty breathing

Overdose classifications (high-level)

Classification Official Regulatory Statement
Severity classification Regulatory documents suggest a low acute toxicity based on documented overdose reports
Regulatory basis FDA Prescribing Information / Health Authority Monograph
Overdose-context constraints Liver function must be immediately evaluated if symptoms suggestive of liver injury (e.g., jaundice, dark urine, or persistent nausea) are reported

Resulting overdose structure

Official overdose statements:

  • Documented acute overdose symptoms commonly involve gastrointestinal effects and neurological effects.
  • Immediate evaluation of the patient's liver function is required if specific symptoms suggestive of liver injury are observed.
  • Treatment is focused on symptomatic and supportive therapy, as official labeling confirms that no specific antidote is known.

Connection to the overall overdose profile (3 sentences): The official overdose profile is defined by the management of common acute symptoms, such as headache and vomiting. Since no specific antidote is known, emergency protocol mandates supportive care and the potential use of activated charcoal. This requires patients to seek immediate medical attention for acute overdose or for the prompt evaluation of any signs indicating severe systemic effects, particularly concerning the liver.

Therapeutic Uses of Dingke

Dingke may be part of symptomatic management for conditions presenting with discomfort, inflammation, or fever. Its use aligns with established guidance for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for the management of symptoms. It supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.

Therapeutic Support

The medication is commonly used to help with symptom clusters that may become intense or disruptive, such as those related to physical discomfort (like headaches and general aches), inflammatory states (tenderness and swelling), and systemic imbalance (fever). It is relevant for easing symptoms that interfere with daily comfort. Dingke contributes to easing the overall symptom load and supports general well-being during symptomatic phases. It is relevant in clinical settings marked by heightened patient distress, such as following minor procedures or during acute episodes of illness.


Quick Fact: Relief for Physical Discomfort and Systemic Imbalance


Eligibility and Restrictions for Use

Oral Dingke (Terbinafine Hydrochloride) eligibility is strictly defined by regulatory bodies based on organ function, physiological status, and age. The medicine is absolutely contraindicated in patients with chronic or active liver disease and in individuals with a known history of hypersensitivity or allergic reaction to oral terbinafine.

Use is generally not recommended for several populations where safety data is limited or risk is elevated. This includes pregnant individuals, breastfeeding mothers (as the drug is excreted in breast milk), and patients with severe renal impairment (creatinine clearance le 50 mL/min), as use has not been adequately studied in this group.

While use is established in adults, the safety and efficacy of the tablet formulation are not established for pediatric patients for fungal nail infections. For children, eligibility is indication-dependent. Specific caution is also required for patients with pre-existing conditions like Systemic Lupus Erythematosus or Psoriasis, due to official reports of potential exacerbation of these underlying diseases. Older adults should be treated with caution, considering the higher frequency of decreased organ function in this age group.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Drug interactions can alter the effect of a medicine, either by increasing its concentration and risk of side effects, or by decreasing its concentration and reducing its efficacy. Interactions may occur between a medicine and other prescription drugs, over-the-counter medicines, herbal supplements, or certain foods and beverages.

Potential interactions involving Dingke should be discussed with a healthcare provider, as they may require close monitoring or adjustment of treatment.

  • Pharmacokinetic Interactions: These occur when one substance affects the absorption, distribution, metabolism, or excretion of another. Many drug-drug interactions are mediated by changes in drug-metabolizing liver enzymes (such as the cytochrome P450 system) or drug transporters. Combining medicines that affect the same metabolic pathway can result in unintended changes to the blood levels of Dingke or the interacting product.

  • Pharmacodynamic Interactions: These occur when two medicines have additive, synergistic, or opposing effects on the body's physiological systems. For example, combining Dingke with other substances that cause similar effects could lead to an exaggerated response, while combining it with an opposing agent could reduce its clinical benefit.

  • Food and Supplements: Certain dietary components or herbal supplements may influence how Dingke is absorbed or processed by the body. This includes well-known interactions involving products like grapefruit and certain enzyme systems, or high-potassium foods and certain cardiovascular medications. Always provide a full list of products being consumed to ensure proper guidance and monitoring.

Mechanism of Action

Targeted Inhibition of Fungal Membrane Synthesis

Dingke (Terbinafine Hydrochloride) exerts its action through a selective disruption of the fungal cell's primary defense structure—its membrane. The mechanism initiates by acting as a selective inhibitor of the Squalene Epoxidase (SQLE) enzyme, an early and critical step in the fungal ergosterol biosynthesis pathway. By halting this process, the drug prevents the production of ergosterol, the key structural lipid necessary for the stability and function of the fungal cell membrane.

Dual-Action Lysis via Toxic Accumulation

The physiological outcome of this enzyme blockade is two-fold. First, the lack of ergosterol causes immediate structural deficiency. Second, the precursor molecule, squalene, is unable to be metabolized and rapidly accumulates to toxic concentrations inside the cell. This toxic accumulation physically compromises the fungal cell membrane from within, leading to irreversible structural damage, severe functional impairment, and resulting in the lysis (destruction) of the pathogen.

Dosage and Administration Information

How to Use Dingke (Terbinafine Hydrochloride)

Dingke is administered through distinct routes based on the target infection: oral for systemic treatment and topical for localized dermatologic use. The standard adult systemic regimen is a fixed dose of 250 mg, taken once daily.


Official Administration Protocol

Property Usage Principle
Administration Route Oral (Tablets or Granules) and Topical (Cream, Gel, or Spray).
Standard Dosing Fixed 250 mg once daily for adults.
Duration of Use 6 weeks for fingernail infections; 12 weeks for toenail infections.
Timing Relative to Food Oral tablets may be taken independent of meals. Oral granules must be taken with food

Special Labeled Conditions and Preparation

Systemic treatment requires adherence to specific administration conditions. The oral granules must be sprinkled onto a small portion of non-acidic soft food and swallowed entirely without being chewed. This ensures the correct delivery of the active substance. The dosing for pediatric patients is adjusted by body weight, utilizing the 125 mg or 187.5 mg granule packets once daily.

Furthermore, the initiation of systemic therapy is procedurally conditioned on a prior assessment of liver function, and the drug is generally not recommended for use in individuals who have a creatinine clearance below 50 mL/min. Topical forms are strictly for external application and must not be used near the eyes or other mucous membranes. The full clinical effect, particularly in treating nail infections, is observed gradually over several months following the completion of the prescribed duration, corresponding to the time needed for healthy nail regrowth.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dingke (Terbinafine)

This section provides a non-advisory, high-level summary of the clinical research conducted on the active ingredient, Terbinafine, focusing on the types of studies, outcomes measured, and populations examined, as reported in authoritative scientific and regulatory literature.


Evidence for Use in Fungal Nail Infections (Onychomycosis)

The evidence base for using the oral form of Dingke for fungal nail infections relies on Randomized Controlled Trials (RCTs) and systematic reviews. Research examined how symptoms evolved in the observed populations, with outcomes related to physical discomfort and the visible condition of the nail. Studies monitored how nail appearance changed and whether the fungus could still be detected in lab tests (mycological findings).

Findings indicated clearance measurements were commonly reported by the researchers. However, studies also report that full clinical measurements often requires long follow-up durations because of the slow growth rate of the nail. What was observed in some studies suggests that definitions of clinical measurements sometimes varied across different trials, which can make it challenging to directly compare all research.

Evidence for Use in Fungal Skin Infections (Tinea Pedis, Cruris, Corporis)

The topical forms of Dingke was studied for conditions involving periods of heightened symptoms, such as athlete's foot and ringworm. This evidence mainly comes from short-term randomized trials that compared the topical preparation against an inactive base. Reports frequently indicated negative tests within the short study periods, and studies documented that certain patterns related to initial response were observed. Research provides context but not individual predictions about the durability of the clearance, as follow-up durations were limited in many of these topical studies.

Long-Term Studies and Follow-up Durability

Long-term follow-up studies are relevant in trials assessing short-term or episodic symptom patterns to understand the durability of the response. Because nails grow slowly, clinical endpoints can only be confirmed after many months. These studies monitored whether fungal infections returned after the medication was stopped (recurrence rates). Data show patterns related to recurrence, but the findings were mixed across the published literature. There is limited information for long-term outcomes regarding the risk of recurrence beyond two years for many patients.

Key Studies & References

  1. Tinea capitis treatment and management

Frequently Asked Questions (FAQ)

Common questions about Dingke (FAQ)

Q: How quickly can a person generally expect to feel the effects of Dingke?

Studies show that oral Dingke works by building up in the skin and nails to fight the infection. For fungal nail infections, the full physical benefit is only observed gradually over several months after the treatment course is finished. This duration corresponds to the time necessary for the healthy, uninfected nail to fully regrow.


Q: How is Dingke different from other medicines used for the same purpose?

According to the official classification, Dingke is an allylamine antifungal agent. This means it works by selectively stopping an enzyme called Squalene Epoxidase, which is necessary for the fungal cell to build its structural wall. This selective action is a key feature that distinguishes it from other general antifungal drug classes.


Q: Is Dingke safe for older adults to use?

Regulatory documents indicate that older adults should be treated with caution. This is primarily because older individuals may have a higher frequency of reduced organ functions, particularly in the kidneys or liver. For this reason, official guidance suggests that a healthcare provider should assess potential risks in this age group.


Q: Are there any known issues with Dingke and high blood pressure medication?

Official product information states that Dingke is a potent inhibitor of the CYP2D6 enzyme, which processes many other medications in the body. Certain heart medications, including some antiarrhythmics and specific beta-blockers often used for high blood pressure, are processed by this enzyme system. Combining them may require monitoring or adjustment of the co-administered drug, according to the official label.


Q: Are there any specific foods I should avoid while on Dingke?

The oral tablets can be taken independent of food. If using the oral granules, however, the oral granules are directed to be mixed with a non-acidic soft food. While not a universal instruction, official labeling advises caution with substances that affect certain drug-metabolizing enzyme systems, which can include products like grapefruit.


Q: How does Dingke's mechanism of action compare to older treatments?

Dingke’s mechanism results in a fungicidal effect, meaning it actively kills the fungal cells. This is achieved by selectively inhibiting a specific enzyme called Squalene Epoxidase. This fungicidal action is often cited as a difference compared to older antifungal agents that may only be fungistatic, which means they inhibit the growth of the fungus without necessarily killing it.


Q: Is Dingke used for things other than the main condition it is approved for?

Dingke is officially approved for the treatment of fungal infections, specifically onychomycosis of the toenail and fingernail for the oral form, and specific Tinea infections for the topical forms. Uses for conditions beyond these approved indications are not included in the official regulatory product information.


Q: What happens if I stop taking Dingke?

The official product instructions state the required duration of the full course of treatment. If the medicine is stopped too early, the infection may not be fully eliminated, potentially leading to the return of the infection and making future treatment more challenging.


Q: Is Dingke known to cause weight gain or loss?

Weight changes are not listed among the most common adverse reactions. However, weight loss has been documented in post-marketing experience and is sometimes attributed to a loss of appetite or severe taste disturbance, which are known side effects. Weight gain is generally not noted in official documents as a common adverse reaction.


Q: Does Dingke affect sleep patterns?

According to official regulatory documents, insomnia, or difficulty sleeping, has been reported as an uncommon side effect in either clinical trials or post-marketing experience. This is sometimes reported alongside other central nervous system effects, such as dizziness or headaches.


Q: Is it normal to feel a little dizzy when first starting Dingke?

Official product information lists dizziness as an uncommon adverse reaction that has been reported. Since it is not a 'Very Common' or 'Common' side effect, Official documents state that patients should inform their healthcare provider if dizziness occurs.


Q: Can Dingke cause mood changes or emotional side effects?

Regulatory records indicate that mood-related issues, including depressive symptoms, anxiety, and feelings of sadness, have been reported in post-marketing experience. These emotional side effects are sometimes noted when the patient experiences a severe taste disturbance or loss of appetite.


Q: Is there a generic version of Dingke available?

Yes, the active ingredient in Dingke, Terbinafine Hydrochloride, is available in generic versions for both the oral tablet and the various topical forms. The FDA's Orange Book lists various generic products that contain this active ingredient.


Q: Are there any warnings about taking Dingke with grapefruit products?

Grapefruit products are widely known to influence certain drug-metabolizing enzymes in the body. While specific drug-drug interaction studies involving Dingke and grapefruit juice are not always explicitly detailed in the labeling, general caution is advised whenever consuming products that can affect the body’s ability to process medicines.


Q: Is Dingke considered a controlled substance?

Dingke, which contains the active ingredient Terbinafine Hydrochloride, is not listed as a controlled substance by the US Drug Enforcement Administration (DEA) or equivalent international bodies. Therefore, its distribution is not regulated under controlled substance laws.


Q: Are there any restrictions on driving or operating machinery while using Dingke?

Official documents indicate that formal studies specifically assessing the drug's effect on driving or operating heavy machinery have not been conducted. However, official guidance suggests that potential impairment should be considered due to reported side effects such as dizziness or visual disturbances.


Q: Why does the packaging say to avoid alcohol while using Dingke?

Dingke is associated with a rare but serious risk of liver problems, including liver failure, and requires liver function monitoring before treatment. Since alcohol is also known to stress the liver, avoiding its consumption is intended to reduce the potential combined risk of liver toxicity, according to warnings in the official product information.


Q: What if I experience a rare but serious side effect listed in the drug facts?

The official patient information describes that signs of a serious side effect, such as liver problems or a severe skin reaction, warrant immediate cessation of the medicine and seeking urgent medical attention. These instructions are detailed in the warnings section of the drug's label.


Q: Can Dingke interact with over-the-counter pain relievers like ibuprofen?

The official labeling contains a recommendation that a healthcare provider should be informed of all over-the-counter (OTC) medicines being taken. While specific interactions with pain relievers like ibuprofen are not always noted in the drug-drug interaction section, a provider can assess for potential overlapping effects (pharmacodynamic interactions) that could still occur.


Q: Has Dingke been recalled or flagged for safety issues?

While the official safety documents contain warnings about rare but potentially severe adverse events, such as liver failure and serious skin reactions, these warnings lead to mandatory testing protocols, not a general recall of the drug. Regulatory bodies issue public warnings and safety requirements rather than a blanket recall for these risks.


Q: What is the risk of dependence or addiction with Dingke?

Regulatory bodies have not scheduled Dingke as a controlled substance, and there is no evidence documented in official labeling to suggest that the medicine carries a risk of dependence or addiction.


Q: How long does Dingke stay in your system?

According to pharmacokinetic data, the elimination half-life from the bloodstream is approximately 36 hours. However, Dingke accumulates in the skin and nails to fight the infection, meaning it can remain present and detectable in these tissues for several weeks or even months after a person has stopped taking the medicine.


Q: Is it possible to take Dingke and still get sick from the condition it treats?

Clinical trial data, while supportive of the drug's efficacy, reports success and clearance rates that are not 100%. This means that some individuals may still experience treatment failure or recurrence. For nail infections, the full clinical benefit depends on the slow regrowth of the healthy nail, which takes several months.


Q: Why is it necessary to take Dingke exactly as directed?

Official product guides state that taking the medication precisely as directed helps maintain the consistent concentration of the drug in the bloodstream and the target tissues. Consistent concentration is necessary to maximize the fungicidal effect and reduce the risk of treatment failure, especially given the lengthy nature of nail infections.


Q: Does Dingke interact with birth control pills?

Specific drug interaction studies have been conducted involving Dingke and certain types of oral contraceptives. Official labeling generally states that Dingke does not affect the processing of some of the components in oral contraceptives. The official labeling contains a recommendation that individuals should confirm their specific medications with a healthcare provider.


Q: Are there any reported cases of Dingke causing vision problems?

Official regulatory documentation indicates that visual disturbances have been reported in both clinical trials and through post-marketing surveillance. These reports have included reduced visual acuity and changes observed in the ocular lens and retina.


Q: Can Dingke affect the results of certain medical tests?

Yes, official safety information indicates that Dingke can cause temporary abnormalities in liver function tests. It can also cause a transient decrease in absolute lymphocyte counts (a type of white blood cell) and, in very rare cases, serious blood disorders like neutropenia.


Q: What are the signs of a serious interaction mentioned in the official guides?

While official documents do not explicitly list the signs of every possible serious drug interaction, the symptoms of related serious side effects (like jaundice for liver issues or unexplained bleeding for blood disorders) can be warning signs. A serious interaction may also manifest as an exaggerated side effect of the other medicine being taken.


Q: Does the time of day matter when taking Dingke?

Dingke is directed to be taken 'once daily.' To ensure consistent concentrations, instructions state that the dose should be taken at approximately the same time each day. Official instructions do not mandate a specific morning or evening time for administration.


Q: Is it true that Dingke can cause dry mouth?

Dry mouth (xerostomia) has been reported as an adverse reaction in the post-marketing surveillance of the drug. While it is noted in official documentation, dry mouth is not typically classified among the most common side effects listed in the primary clinical trials.


Q: Can I use Dingke if I am planning to become pregnant?

Available data from animal studies and limited human information does not suggest that Dingke reduces fertility in men or women. However, the drug is generally not recommended during pregnancy. For individuals who are actively planning a pregnancy, official guidance suggests that a healthcare provider should be consulted regarding treatment options.

How should Dingke be stored and disposed of?

How to Store and Dispose of Dingke?

Dingke (Terbinafine Hydrochloride) must be stored and handled according to the instructions provided in its official regulatory labeling to maintain stability and safety.

Storage Conditions

Oral tablets and topical forms must be stored at controlled room temperature, generally below 30, C. The oral tablets require storage in their original package and must be protected from light. The topical cream has the explicit constraint: Do not freeze.

Special Handling and Safety

All forms of this medication must be stored out of the sight and reach of children. Additionally, certain topical forms carry a warning that materials contacting the product may pose a serious fire hazard near naked flames.

Disposal

Any unused or expired product must be disposed of promptly and in accordance with local requirements, typically through a formal drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dingke found in:

A-Z Index: